share_log

Wedbush Maintains Neutral on Apellis Pharmaceuticals, Raises Price Target to $67

Wedbush Maintains Neutral on Apellis Pharmaceuticals, Raises Price Target to $67

Wedbush 對阿佩利斯製藥保持中立,將目標價上調至67美元
Benzinga Real-time News ·  2022/09/12 09:48

Wedbush analyst Laura Chico maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral and raises the price target from $55 to $67.

Wedbush分析師勞拉·奇科維持Apellis Pharmicals(納斯達克股票代碼:APLS)爲中性,並將目標股價從55美元上調至67美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論